Parathyroid hormone for osteoporosis

References

Citations

1. Neer RM, et al. (2001). Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine, 344(19): 1434–1441.

2. Drugs for prevention and treatment of postmenopausal osteoporosis (2005). Treatment Guidelines From the Medical Letter, 3(38): 69–74.

3. Abramowicz M (2003). Teriparatide (Forteo) for osteoporosis. Medical Letter on Drugs and Therapeutics, 45(1149): 9–10.

4. Black DM, et al. (2003). The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. New England Journal of Medicine, 349(13): 1207–1215.

5. Finklestein JS, et al. (2003). The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. New England Journal of Medicine, 349(13): 1216–1226.

6. Black DM, et al. (2005). One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. New England Journal of Medicine, 353(6): 555–565.

Author:	Robin Parks, MS	Last Updated: December 1, 2006
Medical Review:	Joy Melnikow, MD, MPH - Family Medicine Carla J. Herman, MD, MPH - Internal Medicine
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.